Ferring gains option for bladder cancer gene therapy
FKD Therapies Oy (Kuopio, Finland) granted Ferring Pharmaceuticals A/S (Saint-Prex, Switzerland) an option to license exclusive, worldwide commercial rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3; formerly instiladrin). The adenovirus serotype 5 (Ad5) vector containing interferon (IFN) alfa-2b is in Phase III testing to treat high-grade non-muscle invasive bladder cancer (NMIBC) patients unresponsive to Bacillus Calmette-Guérin (BCG) therapy. Financial terms were undisclosed.
The option is exercisable following FDA approval. Paul Navarre, CEO of Ferring's U.S. unit, told BioCentury Ferring will create a U.S. oncology division now for the launch of rAd-IFN/Syn3. Final Phase III data is expected in 2019, according to Ferring EVP and CMO Klaus Dugi...